Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Antihypertensive (Reserpine)/Discontinued

HYSERPIN

HYSERPIN

Clinical safety rating

caution

Comprehensive clinical and safety monograph for HYSERPIN (HYSERPIN).


Mechanism of Action

Hyserpin is a combination of reserpine and hydralazine. Reserpine depletes catecholamines and serotonin from nerve endings by inhibiting vesicular monoamine transporter (VMAT). Hydralazine is a direct arteriolar vasodilator that reduces peripheral resistance via relaxation of vascular smooth muscle, possibly through nitric oxide-mediated pathways.

What the body does with it

MetabolismReserpine: extensively metabolized in the liver via cytochrome P450 enzymes; hydralazine: primarily metabolized by N-acetylation (polymorphic) and oxidation.
ExcretionRenal: 50-60% unchanged; biliary/fecal: 30-40% as metabolites
Half-lifeTerminal elimination half-life: 12-16 hours; clinical context: supports twice-daily dosing for hypertension
Protein binding85-93%; primarily bound to albumin and alpha-1-acid glycoprotein
Volume of Distribution2-4 L/kg; indicates extensive tissue distribution, higher in hypertensive patients
BioavailabilityOral: 50-60%; intramuscular: 70-80%
Onset of ActionOral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes
Duration of ActionOral: 6-12 hours; intravenous/intramuscular: 4-8 hours; prolonged with renal impairment
Molecular WeightReserpine: 608.68 Da; Hydralazine: 160.18 Da; Hydrochlorothiazide: 297.74 Da

Classification & Brands

Dosing & administration

Oral: 0.1-0.25 mg twice daily. Maximum dose: 0.5 mg daily.

Dosage formTABLET
Renal impairmentNot dialyzable. No specific GFR-based adjustments; use with caution in severe impairment.
Liver impairmentChild-Pugh Class B or C: reduce dose by 50% or increase dosing interval (e.g., once daily).
Pediatric useNot recommended due to lack of safety and efficacy data. Avoid in children.
Geriatric useInitiate at 0.05 mg once daily; titrate slowly to minimize hypotension and CNS effects.

Use during pregnancy

1st trimesterHypertension is a combination product containing reserpine, hydralazine, and hydrochlorothiazide. Reserpine crosses the placenta and may cause adverse effects; hydralazine is associated with maternal hypotension and potential fetal hypoxia; hydrochlorothiazide may cause electrolyte imbalances and decreased placental perfusion. Avoid in first trimester.
2nd trimesterUse only if clearly needed; all components have potential fetal risks. Monitor maternal blood pressure closely.
3rd trimesterAvoid near term due to risk of neonatal thrombocytopenia from hydrochlorothiazide, and potential neonatal bradycardia from reserpine.

Clinical note

Comprehensive clinical and safety monograph for HYSERPIN (HYSERPIN).

Placental transferReserpine and hydralazine cross the placenta; hydrochlorothiazide crosses the placenta. All three components have documented placental transfer.
BreastfeedingReserpine is excreted into breast milk and may cause galactorrhea, sedation, and respiratory depression in the infant. Hydralazine and hydrochlorothiazide are also excreted; thiazides may decrease milk production. Avoid breastfeeding.
Lactation RatingL5 - Contraindicated
Teratogenic RiskHypertension itself poses risks to the fetus (e.g., placental insufficiency, growth restriction). For antihypertensives in general: first trimester: no major teratogenicity known for most agents; second/third trimester: risk of fetal hypotension, hypoxia, and growth restriction. Specific to Hyserpin (reserpine): animal studies show possible teratogenic effects; human data limited. Avoid in pregnancy especially third trimester due to risk of neonatal bradycardia, hypothermia, and nasal congestion.
Fetal MonitoringMonitor maternal blood pressure, heart rate, and signs of depression (potential adverse effect). Fetal monitoring: ultrasound for growth, non-stress test or biophysical profile in third trimester if chronic hypertension.
Fertility EffectsReserpine may impair fertility in males due to decreased libido and possible impairment of sexual function. No specific human studies on female fertility; theoretical effect on reproductive hormones (catecholamine depletion).

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to any componentActive peptic ulcer diseaseUlcerative colitisHistory of depression (especially with reserpine)Electroconvulsive therapySevere renal impairment (anuria)Severe hepatic impairmentHypersensitivity to sulfonamide-derived drugs (hydrochlorothiazide)

Clinical Precautions

PrecautionsRisk of mental depression (reserpine), Orthostatic hypotension, Lupus-like syndrome (hydralazine, especially in slow acetylators), Peripheral neuropathy (hydralazine, due to pyridoxine deficiency)
Food/DietaryAvoid excessive intake of tyramine-rich foods (aged cheeses, cured meats, pickled herring, broad beans, soybean products) due to potential hypertensive crisis risk with reserpine. Avoid licorice (glycyrrhiza) as it can worsen hypokalemia induced by hydrochlorothiazide. Limit salt substitutes containing potassium; monitor potassium levels. Avoid grapefruit juice as it may increase reserpine bioavailability. Take with food or milk to reduce gastrointestinal upset.

Clinical Tips & Counseling

Clinical PearlsHyserpin is a combination product of reserpine and hydrochlorothiazide. Reserpine depletes catecholamines, causing bradycardia and orthostatic hypotension; start with low doses and monitor BP closely. Hydrochlorothiazide can cause hypokalemia, hyponatremia, and hyperglycemia; check electrolytes and renal function at baseline and periodically. Avoid use in patients with history of depression, peptic ulcer, or ulcerative colitis due to reserpine. May cause nasal congestion and drowsiness. Use with caution in patients on MAOIs or digitalis.
Patient AdviceTake exactly as prescribed; do not skip doses or stop suddenly. · Rise slowly from sitting or lying down to prevent dizziness. · Avoid alcohol and other sedatives as they may increase drowsiness. · Report weight gain, swelling, or shortness of breath (signs of fluid overload). · May cause nasal stuffiness or vivid dreams; if bothersome, notify your doctor. · Do not use over-the-counter cold or appetite suppressants without consulting your doctor. · May cause sensitivity to sunlight; use sunscreen and protective clothing. · Regular monitoring of blood pressure and lab tests (potassium, glucose) is essential.

HYSERPIN Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

External sources

DailyMed (NIH) PubMed OpenFDA